Personal information

No personal information available

Activities

Collapse all

Works (6)

Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent blindness

Experimental Eye Research
2023-07 | Journal article
DOI: 10.1016/j.exer.2023.109444
Contributors: Najam A. Sharif
Source: check_circle
Crossref

FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma

Experimental Eye Research
2023-04 | Journal article
DOI: 10.1016/j.exer.2023.109415
Contributors: Najam A. Sharif; Noriko Odani-Kawabata; Fenghe Lu; Leonard Pinchuk
Source: check_circle
Crossref

PAF‐induced inflammatory and immuno‐allergic ophthalmic diseases and their mitigation with PAF receptor antagonists: Cell and nuclear effects

BioFactors
2022-11 | Journal article
DOI: 10.1002/biof.1848
Contributors: Najam A. Sharif
Source: check_circle
Crossref

Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810

ACS Pharmacology & Translational Science
2020-12-11 | Journal article
DOI: 10.1021/acsptsci.0c00137
Contributors: Najam A. Sharif
Source: check_circle
Crossref

Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma

British Journal of Pharmacology
2019-04 | Journal article
DOI: 10.1111/bph.14327
Contributors: Peter G Klimko; Najam A Sharif
Source: check_circle
Crossref

Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility

British Journal of Pharmacology
2019-04 | Journal article
DOI: 10.1111/bph.14335
Contributors: Najam A Sharif; Peter G Klimko
Source: check_circle
Crossref
How many people are using ORCID?